Efficacy and toxicity of CLAG combined with pegylated liposomal doxorubicin in the treatment of refractory or relapsed acute myeloid leukemia

Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel

(2022) Hartmut Döhner et al.   BLOOD

NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021

(2021) Daniel A. Pollyea et al.   Journal of the National Comprehensive Cancer Network

Improved outcome of children with relapsed/refractory acute myeloid leukemia by addition of cladribine to re‐induction chemotherapy

(2021) Min Ruan et al.   Cancer Medicine

Long‐term follow‐up of Cladribine, high‐dose Cytarabine and Idarubicin as salvage treatment for Relapsed acute myeloid Leukemia and Literature Review

(2020) Karin Mayer et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Cladribine‐based salvage regimen‐induced deep remission of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in leukemia phase

(2020) Han Yao et al.   HEMATOLOGICAL ONCOLOGY

Efficacy of mitoxantrone-based salvage therapies in relapsed or refractory acute myeloid leukemia in the Mayo Clinic Cancer Center: Analysis of survival after ‘CLAG-M’ vs. ‘MEC’

(2020) Caleb J Scheckel et al.   LEUKEMIA RESEARCH

Comparison of High-Dose Cytarabine, Mitoxantrone, and Pegaspargase (HAM-pegA) to High-Dose Cytarabine, Mitoxantrone, Cladribine, and Filgrastim (CLAG-M) as First-Line Salvage Cytotoxic Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia

(2020) Ciera L. Patzke et al.   Journal of Clinical Medicine

Cladribine with Granulocyte Colony‐Stimulating Factor, Cytarabine, and Aclarubicin Regimen in Refractory/Relapsed Acute Myeloid Leukemia: A Phase II Multicenter Study

(2020) Hua Wang et al.   ONCOLOGIST

Heterogeneity in refractory acute myeloid leukemia

(2019) Sachi Horibata et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Pegylated liposomal doxorubicin for myeloid neoplasms

(2019) Cheng Zhang et al.   ANTI-CANCER DRUGS

A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis

(2018) Mahasweta Gooptu et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Molecular Minimal Residual Disease in Acute Myeloid Leukemia

(2018) Mojca Jongen-Lavrencic et al.   NEW ENGLAND JOURNAL OF MEDICINE

Analysis of Efficacy and Prognostic Factors of CLAG Treatment in Chinese Patients with Refractory or Relapsed Acute Myeloid Leukemia

(2018) Li Wang et al.   ACTA HAEMATOLOGICA

Cladribine in the remission induction of adult acute myeloid leukemia: where do we stand?

(2018) Ayman Qasrawi et al.   ANNALS OF HEMATOLOGY

Phase 1/2 trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms

(2018) Anna B. Halpern et al.   HAEMATOLOGICA

How to prevent relapse after allogeneic hematopoietic stem cell transplantation in patients with acute leukemia and myelodysplastic syndrome

(2017) N. Yafour et al.   Current Research in Translational Medicine

Cladribine, cytarabine and idarubicin (CLA-Ida) salvage chemotherapy in relapsed acute myeloid leukemia (AML)

(2016) Chantal Fridle et al.   LEUKEMIA & LYMPHOMA

Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia

(2015) Nestor Ramos et al.   Journal of Clinical Medicine

MRD in AML: It is time to change the definition of remission

(2014) Gert J. Ossenkoppele et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Conditioning regimens for hematopoietic cell transplantation: one size does not fit all

(2014) B. Gyurkocza et al.   BLOOD

Minimal residual disease in acute myeloid leukaemia

(2013) Christopher S. Hourigan et al.   Nature Reviews Clinical Oncology